![RD white paper (1200 x 500 px)-May-22-2024-10-30-48-7074-PM RD white paper (1200 x 500 px)-May-22-2024-10-30-48-7074-PM](https://discover.emmes.com/hs-fs/hubfs/RD%20white%20paper%20%20(1200%20x%20500%20px)-May-22-2024-10-30-48-7074-PM.png?width=1200&height=500&name=RD%20white%20paper%20%20(1200%20x%20500%20px)-May-22-2024-10-30-48-7074-PM.png)
Shorten Start-Up Timelines in Vaccine Trials
Six Factors Critical to Success
Speed is crucial in clinical development, especially for infectious disease vaccine trials. Factors like competition and global health crises make time-to-market vital. The COVID pandemic has set a new standard for vaccine development, with some trials completing in under a year. Prioritization and special waivers helped achieve this speed, resetting expectations. We believe that six areas are most significant in impacting the efficiency of the study start-up phase:
Download our ebook to gain insights and strategy in how to:
- Leverage local expertise to avoid delays
- Engage key personnel early to ensure alignment
- Navigate regulatory and ethical approvals efficiently
- Develop and implement a robust operational plan
- Develop effective recruitment strategies
- Harness technology to accelerate building the trial database